NovoCure Stock Forecast, Price & News

NovoCure's stock was trading at $67.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVCR stock has increased by 155.0% and is now trading at $171.84.
View which stocks have been most impacted by COVID-19.

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NovoCure stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCR, but not buy additional shares or sell existing shares.
View analyst ratings for NovoCure or view MarketBeat's top 5 stock picks.

Wall Street analysts have given NovoCure a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NovoCure wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

1,448 employees have rated NovoCure CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among NovoCure's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

NovoCure is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for NovoCure.

NovoCure will be holding an earnings conference call on Thursday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

NovoCure Limited (NASDAQ:NVCR) issued its earnings results on Thursday, October, 29th. The medical equipment provider reported $0.09 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.04 by $0.05. The medical equipment provider had revenue of $132.70 million for the quarter, compared to analyst estimates of $120.02 million. NovoCure had a return on equity of 7.40% and a net margin of 4.26%. NovoCure's revenue for the quarter was up 44.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.02 earnings per share.
View NovoCure's earnings history.

NovoCure updated its FY 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $494.4-494.4 million, compared to the consensus revenue estimate of $482.29 million.

9 Wall Street analysts have issued 12-month target prices for NovoCure's shares. Their forecasts range from $58.00 to $159.00. On average, they expect NovoCure's share price to reach $112.38 in the next twelve months. This suggests that the stock has a possible downside of 34.6%.
View analysts' price targets for NovoCure or view Wall Street analyst' top-rated stocks.

NovoCure saw a increase in short interest in December. As of December 31st, there was short interest totaling 5,880,000 shares, an increase of 17.8% from the December 15th total of 4,990,000 shares. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is currently 5.0 days. Currently, 6.8% of the company's shares are sold short.
View NovoCure's Short Interest.

Some companies that are related to NovoCure include Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Fresenius SE & Co. KGaA (FSNUY), Insulet (PODD), Teleflex (TFX), Abiomed (ABMD), Penumbra (PEN), iRhythm Technologies (IRTC), Hill-Rom (HRC), Globus Medical (GMED), Nevro (NVRO), Haemonetics (HAE) and Inspire Medical Systems (INSP).
View all of NVCR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy Partners (VNOM), Roku (ROKU), salesforce.com (CRM) and Square (SQ).

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

NovoCure's stock is owned by a variety of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.12%), Scout Investments Inc. (0.10%), Peregrine Capital Management LLC (0.07%), Northstar Asset Management LLC (0.02%), TIAA FSB (0.01%) and Total Clarity Wealth Management Inc. (0.01%). Company insiders that own NovoCure stock include Asaf Danziger, Ashley Cordova, Charles G Phillips III, Ely Benaim, Gabriel Leung, Jeryl L Hilleman, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends for NovoCure.

NVCR stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Peregrine Capital Management LLC, Exchange Traded Concepts LLC, Sowell Financial Services LLC, Scout Investments Inc., Northstar Asset Management LLC, and Total Clarity Wealth Management Inc.. Company insiders that have sold NovoCure company stock in the last year include Asaf Danziger, Ashley Cordova, Ely Benaim, Gabriel Leung, Jeryl L Hilleman, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen, and William F Doyle.
View insider buying and selling activity for NovoCure or view top insider-selling stocks.

NVCR stock was purchased by a variety of institutional investors in the last quarter, including TIAA FSB, Brookstone Capital Management, Kestra Advisory Services LLC, Sheets Smith Wealth Management, Kovack Advisors Inc., Redpoint Investment Management Pty Ltd, XR Securities LLC, and Diversified Trust Co.
View insider buying and selling activity for NovoCure or or view top insider-buying stocks.

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVCR stock can currently be purchased for approximately $171.84.

NovoCure has a market capitalization of $17.49 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. NovoCure employs 782 workers across the globe.

The official website for NovoCure is www.novocure.com.

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]